The DOI matches its Crossref record; 50 of the 51 references it cites were found in a registry or an index.
VEGFA-VEGFR Pathway Blockade Inhibits Tumor-Induced Regulatory T-cell Proliferation in Colorectal Cancer
Published version of a preprint
Abstract
Multitarget antiangiogenic tyrosine kinase inhibitors (TKI) have been shown to reduce regulatory T cells (Treg) in tumor-bearing animals and patients with metastatic renal carcinomas. However, a direct role of the VEGF-A/VEGFR pathway inhibition in this phenomenon is a matter of debate and molecular mechanisms leading to Treg modulation in this setting have not been explored to date. Treg proportion, number, and proliferation were analyzed by flow cytometry in peripheral blood of patients with metastatic colorectal cancer (mCRC) treated with bevacizumab, a monoclonal antibody targeting specifically VEGF-A, and in colon cancer-bearing mice (CT26) treated with drugs targeting the VEGF/VEGFR axis. The direct impact of VEGF-A on Treg induction was assessed together with specific blockade of different isoforms of VEGFRs that may be involved. In CT26-bearing mice, anti-VEGF antibody and sunitinib treatments reduced Treg but masitinib, a TKI not targeting VEGFR, did not. Targeting VEGF-A/VEGFR axis seems sufficient to affect Treg percentages, without any changes in their function. Similarly, bevacizumab inhibited Treg accumulation in peripheral blood of patients with mCRCs. In vitro, Treg expressing VEGFR from tumor-bearing mice directly proliferated in response to VEGF-A. Anti-VEGF-A treatment decreased Treg proliferation in mice as well as in patients with mCRCs. VEGFR-2- but not VEGFR-1-specific blockade led to the same results. We identified a novel mechanism of tumor escape by which VEGF-A directly triggers Treg proliferation. This proliferation is inhibited by VEGF-A/VEGFR-2 blockade. Anti-VEGF-A therapies also have immunologic effects that may be used with a therapeutic goal in the future.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“VEGFA signaling is directly involved in TREG cell expansion”
From Immunomodulation by targeted anticancer agents (2021) · cites this paper as Terme et al., 2013
In the citing paper
“TREG cells express CDK4/CDK6 as well as VEGF receptors (Goel et al., 2017; Terme et al., 2013) and hence are particularly sensitive to CDK4/CDK6 inhibitors and bevacizumab”
From Immunomodulation by targeted anticancer agents (2021) · cites this paper as Terme et al., 2013
In the citing paper
“Secondly, VEGF could inhibit the maturation of DC, induce the exhaustion of T cells, promote the proliferation of Tregs, and increase the ratio of MDSCs [90–93].”
From Combination strategies with PD-1/PD-L1 blockade: current advances and future directions (2022) · cites this paper as [92]
Citations
Cites
Type, Density, and Location of Immune Cells Within Human Colorectal Tumors Predict Clinical Outcome
Galon, J., Costes, A., Sanchez-Cabo, F., Kirilovsky, A., Mlecnik, B., Lagorce-Pagès, C., Tosolini, M., Camus, M., Berger, A., Wind, P., et al. (2006) · Science · doi:10.1126/science.1129139 · Cited by 6,516 · cited 1×
“This infiltration may also be a major predictor of tumor recurrence and patient survival (3).”
BackgroundThornton, A. M., & Shevach, E. M. (1998) · The Journal of Experimental Medicine · doi:10.1084/jem.188.2.287 · Cited by 2,639
Comprehensive analysis of kinase inhibitor selectivity
Davis, M. I., Hunt, J. P., Herrgard, S., Ciceri, P., Wodicka, L. M., Pallares, G., Hocker, M., Treiber, D. K., & Zarrinkar, P. P. (2011) · Nature Biotechnology · doi:10.1038/nbt.1990 · Cited by 2,409 · cited 1×
“Masitinib is currently the most selective TKI in clinical development or already approved to date (20, 21).”
BackgroundGiantonio, B. J., Catalano, P. J., Meropol, N. J., O'Dwyer, P. J., Mitchell, E. P., Alberts, S. R., Schwartz, M. A., & Benson, A. B. (2007) · Journal of Clinical Oncology · doi:10.1200/jco.2006.09.6305 · Cited by 2,279
Effector Memory T Cells, Early Metastasis, and Survival in Colorectal Cancer
Pagès, F., Berger, A., Camus, M., Sanchez-Cabo, F., Costes, A., Molidor, R., Mlecnik, B., Kirilovsky, A., Nilsson, M., Damotte, D., et al. (2005) · New England Journal of Medicine · doi:10.1056/nejmoa051424 · Cited by 2,135 · cited 9×
“Elevated numbers of intratumoral cytotoxic and memory T cells (CD8þ and CD45ROþ, respectively) have been shown to correlate with an aggressive phenotype reflected by tumor microinvasive status (2).”
BackgroundInfluentialGabrilovich, D. I., Chen, H. L., Girgis, K. R., Cunningham, H. T., Meny, G. M., Nadaf, S., Kavanaugh, D., & Carbone, D. P. (1996) · Nature Medicine · doi:10.1038/nm1096-1096 · Cited by 1,977 · cited 3×
“If an indirect action through VEGF-induced immature dendritic cells (DC) has been suggested (14, 15), the direct effect of VEGF-A on Treg has never been studied.”
BackgroundTumour hypoxia promotes tolerance and angiogenesis via CCL28 and Treg cells
Facciabene, A., Peng, X., Hagemann, I. S., Balint, K., Barchetti, A., Wang, L.-P., Gimotty, P. A., Gilks, C. B., Lal, P., Zhang, L., et al. (2011) · Nature · doi:10.1038/nature10169 · Cited by 1,376
Comprehensive assay of kinase catalytic activity reveals features of kinase inhibitor selectivity
Anastassiadis, T., Deacon, S. W., Devarajan, K., Ma, H., & Peterson, J. R. (2011) · Nature Biotechnology · doi:10.1038/nbt.2017 · Cited by 919 · cited 1×
“Masitinib is currently the most selective TKI in clinical development or already approved to date (20, 21).”
BackgroundGhiringhelli, F., Puig, P. E., Roux, S., Parcellier, A., Schmitt, E., Solary, E., Kroemer, G., Martin, F., Chauffert, B., & Zitvogel, L. (2005) · The Journal of Experimental Medicine · doi:10.1084/jem.20050463 · Cited by 776
Gobert, M., Treilleux, I., Bendriss-Vermare, N., Bachelot, T., Goddard-Leon, S., Arfi, V., Biota, C., Doffin, A. C., Durand, I., Olive, D., et al. (2009) · Cancer Research · doi:10.1158/0008-5472.can-08-2360 · Cited by 758 · cited 1×
“human, 2 studies have shown an increased proportion of dividing Tregs in tumors or peripheral blood in patients with breast cancer and acute myeloid leukemia (44, 45).”
Background
Cited by
Regulatory T cells in cancer immunosuppression — implications for anticancer therapy
Togashi, Y., Shitara, K., & Nishikawa, H. (2019) · Nature Reviews Clinical Oncology · doi:10.1038/s41571-019-0175-7 · Cited by 1,546
Immunological effects of conventional chemotherapy and targeted anticancer agents
Galluzzi, L., Buqué, A., Kepp, O., Zitvogel, L., & Kroemer, G. (2015) · Cancer Cell · doi:10.1016/j.ccell.2015.10.012 · Cited by 1,530
“Immunological Effects of Targeted Anticancer Agents Agent Setting Effect Notes Reference Bevacizumab transplantable murine CRC depletes TREG cells mechanism involving KDR Terme et al., 2013 Dasatinib CML favors the expansion of circulating CTLs and NK cells correlates with molecular response to chemotherapy Iriyama et…”
BackgroundInfluentialCombination strategies with PD-1/PD-L1 blockade: current advances and future directions
Yi, M., Zheng, X., Niu, M., Zhu, S., Ge, H., & Wu, K. (2022) · Molecular Cancer · doi:10.1186/s12943-021-01489-2 · Cited by 1,445
Thommen, D. S., & Schumacher, T. N. (2018) · Cancer Cell · doi:10.1016/j.ccell.2018.03.012 · Cited by 1,299
“VEGF secretion has been found to affect T cell functionality both directly and indirectly, via suppression of DC maturation and recruitment of suppressive cell populations (Gabrilovich et al., 1998; Terme et al., 2013).”
BackgroundExploring treatment options in cancer: tumor treatment strategies
Liu, B., Zhou, H., Tan, L., Siu, K. T. H., & Guan, X.-Y. (2024) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-024-01856-7 · Cited by 1,201
Metadata
- Authors
- Terme, M., Pernot, S., Marcheteau, E., Sandoval, F., Benhamouda, N., Colussi, O., Dubreuil, O., Carpentier, A. F., Tartour, E., & Taieb, J.
- Affiliations
- Inserm (FR)
- Authors' Affiliations: 1INSERM U970, PARCC (Paris Cardiovascular Research Center), Université Paris-Descartes, Sorbonne Paris Cité; 2Service d'immunologie biologique. Hôpital Européen Georges Pompidou; 3Service d'hépatogastroentérologie et d'oncologie digestive, Hôpital Européen Geroges Pompidou, and 4Université Paris Descartes, Laboratoire de Recherches Biochirurgicales, Hôpital Européen Georges Pompidou, Paris, France
- Venue
- Cancer Research
- Published
- 2013-01-15
- Volume
- 73
- Issue
- 2
- Pages
- 539-549
- ISSN
- 0008-5472 (ISSN-L)
- 1538-7445
- OpenAlex
- W2062783581
- Cited by
- 684
- References
- 51
- Citations by year
- 2026: 30 · 2025: 46 · 2024: 41 · 2023: 59 · 2022: 81 · 2021: 76 · 2020: 84 · 2019: 76 · 2018: 44 · 2017: 33 · 2016: 36 · 2015: 30 · 2014: 24 · 2013: 22
- FWCI
- 9.89
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- Cancer Research (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Angiogenesis and VEGF in Cancer
- Health Sciences › Medicine › Oncology › Cancer Immunotherapy and Biomarkers
- Life Sciences › Immunology and Microbiology › Immunology › T-cell and B-cell Immunology
- Keywords
- regulatory T cells, Treg proliferation, colorectal cancer, metastatic colorectal cancer, bevacizumab, anti-VEGF therapy, VEGFR2, VEGFR1, sunitinib, masitinib, tumor immune evasion, antiangiogenic tyrosine kinase inhibitors
- MeSH terms
- Bevacizumab, Sunitinib, Animals, Cell Count, Colonic Neoplasms, Female, Humans, Indoles, Mice, Inbred BALB C, Pyrroles, Colorectal Neoplasms, Tumor Escape, Angiogenesis Inhibitors, Receptors, Vascular Endothelial Growth Factor, Vascular Endothelial Growth Factor A, Cell Line, Tumor, Cell Proliferation, T-Lymphocytes, Regulatory, Mice, Antibodies, Monoclonal, Humanized
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: VEGFA-VEGFR Pathway Blockade Inhibits Tumor-Induced Regulatory T-cell Proliferation in Colorectal Cancer. https://app.cochat.ai/papers/10.1158/0008-5472.can-12-2325
- The paper
- Terme, M., Pernot, S., Marcheteau, E., Sandoval, F., Benhamouda, N., Colussi, O., Dubreuil, O., Carpentier, A. F., Tartour, E., & Taieb, J. (2013). VEGFA-VEGFR Pathway Blockade Inhibits Tumor-Induced Regulatory T-cell Proliferation in Colorectal Cancer. Cancer Research. https://doi.org/10.1158/0008-5472.can-12-2325
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.